Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prothena Corporation (PRTA)
:PRTA
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.04Last Year’s EPS
-1.34Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 10.35%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
The earnings call presents a balanced outlook for Prothena. While there are significant opportunities for growth through its robust portfolio and strategic partnerships, challenges remain, particularly with the dependency on future clinical trial successes and the narrow miss in prasinezumab's statistical significance.Company Guidance
During the Prothena Biosciences Fourth Quarter and Full Year 2024 Financial Results Conference Call, the company provided guidance for 2025, highlighting several key metrics. Prothena expects full-year 2025 net cash used in operating and investing activities to range between $168 million and $175 million, anticipating a year-end cash balance of approximately $301 million. The projected net loss for 2025 is estimated to be between $197 million and $205 million, inclusive of an estimated $41 million in non-cash share-based compensation expense. As of December 31, 2024, Prothena reported $472.2 million in cash, cash equivalents, and restricted cash, and as of February 20, 2025, the company had approximately 53.8 million ordinary shares outstanding. The company emphasized that it maintains a simple capital structure with zero debt.Robust Portfolio and Strategic Partnerships
Prothena has a robust portfolio with four wholly-owned and four partnered programs across various stages of clinical development, allowing strategic collaborations to advance treatments while maintaining financial benefits.
Birtamimab's Commercial Potential
Birtamimab represents a significant multi-billion dollar global commercial opportunity as the first potential treatment for AL amyloidosis with demonstrated early survival benefit.
Partnerships with Major Pharmaceutical Companies
Collaborations with companies like Roche, Novo Nordisk, and Bristol Myers Squibb enhance the development of prasinezumab, coramitug, and BMS-986446, advancing them as potential transformative treatments.
Strong Financial Position
Prothena ended 2024 with $472.2 million in cash, cash equivalents, and restricted cash, maintaining a simple capital structure with zero debt.
---
PRTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PRTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $13.82 | $13.89 | +0.51% |
| Nov 12, 2024 | $17.36 | $17.23 | -0.75% |
| Aug 08, 2024 | $19.68 | $20.55 | +4.42% |
| May 08, 2024 | $23.03 | $22.00 | -4.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Prothena Corporation (PRTA) report earnings?
Prothena Corporation (PRTA) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Prothena Corporation (PRTA) earnings time?
Prothena Corporation (PRTA) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRTA EPS forecast?
PRTA EPS forecast for the fiscal quarter 2025 (Q1) is -1.04.
---